地诺孕素治疗对子宫内膜异位症患者的临床疗效探讨

The Clinical Efficacy of Dienogest in the Treatment of Endometriosis Patients

目的探讨地诺孕素治疗对子宫内膜异位症患者的临床疗效。方法选择2018年6月—2019年10月在该院治疗的子宫内膜异位症患者70例作为研究对象,随机数表分为对照组(n=35)和观察组(n=35)。对照组给予普通剂量给予治疗,观察组患者使用高剂量的地诺孕素治疗,治疗后对患者效果进行评估,比较两组患者各类疼痛症状指标、不良反应率以及子宫活动受限和附件包块的差异。结果治疗后,观察组痛经症状评分为(2.41±0.09)分、性交痛评分为(1.17±0.13)分、非经期下腹痛评分为(1.45±0.56)分,对照组痛经症状评分为(3.98±0.62)分、性交痛评分为(2.62±0.42)分、非经期下腹痛评分为(2.23±0.35)分,对照组和观察组患者的各类疼痛症状指标均有所下降,观察组治疗后各症状评分下降幅度低于对照组,差异有统计学意义(P<0.05);观察组治疗后主要不良反应中潮热1例(2.86%)、阴道干燥2例(5.71%),总计3例(8.57%)。对照组不良反应中潮热2例(5.71%)、恶心呕吐4例(11.42%)、盗汗3例(8.57%)、阴道干燥4例(11.42%),总计13例(37.14%)。观察组不良反应率为8.57%均低于对照组37.14%,差异有统计学意义(χ^2=8.102,P<0.05);对照组和观察组患者治疗后子宫活动受限率为和附件包块率均有所下降,观察组治疗后下降幅度优于对照组,差异有统计学意义(P<0.05)。结论将高剂量地诺孕素用于子宫内膜异位症患者的临床效果显著,安全性较高,能够有效改善患者的预后生活状况。

Objective To investigate the clinical efficacy of dienogest in patients with endometriosis.Methods 70 patients with endometriosis treated in the hospital from June 2018 to October 2019 were selected as the research objects.The random number table was divided into a control group(n=35)and an observation group(n=35).The control group was treated with ordinary doses,and the observation group was treated with high-dose dinogest.After the treatment,the patient's effect was evaluated,and the two groups were compared with various pain symptoms,adverse reaction rates,uterine activity limitation and accessory block difference.Results After treatment,the score of dysmenorrhea symptom in the observation group,was(2.41±0.09)points,sexual pain was(1.17±0.13)points,non-menstrual lower abdominal pain was(1.45±0.56)points;in the control group,dysmenorrhea symptom was(3.98±0.62)points,sexual pain was(2.62±0.42)points,non-menstrual lower abdominal pain was(2.23±0.35)points,all kinds of pain symptoms decreased in both the control group and the observation group,and the decrease amplitude of each symptom score in the observation group was lower than that in the control group after treatment,and the difference was statistically significant(P<0.05);The main adverse reactions in the observation group after treatment included hot flashes in 1 case(2.86%)and vaginal dryness in 2 cases(5.71%),totaling 3 cases(8.57%).In the control group,there were 2 cases of hot flashes(5.71%),4 cases of nausea and vomiting(11.42%),3 cases of night sweats(8.57%),and 4 cases of vaginal dryness(11.42%),totaling 13 cases(37.14%).The adverse reaction rate of the observation group was 8.57% lower than that of the control group 37.14%,and the difference was statistically significant(χ^2=8.102,P<0.05);the control group and the observation group had uterine activity limitation rate and adnexal mass after treatment The rates all dropped,the observation group dropped better than the control group after treatment,and the difference was statistically significant(P<0.05).Conclusion The high-dose dinogest used in patients with endometriosis has a significant clinical effect,high safety,and can effectively improve the prognostic life of patients.